M Tabaton

List of Publications by Year
in descending order

55 papers	7,505 citations	109321 35 h-index	161849 54 g-index
56 all docs	56 docs citations	56 times ranked	6207 citing authors

#	Article	IF	Citations
1	Transcriptional and postâ€transcriptional regulation of Î²â€secretase. IUBMB Life, 2012, 64, 943-950.	3.4	33
2	The molecular link between Î²- and Î³-secretase activity on the amyloid Î² precursor protein. Cellular and Molecular Life Sciences, 2007, 64, 2211-2218.	5.4	55
3	Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiology of Disease, 2003, 14, 291-301.	4.4	41
4	Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. Neurology, 2003, 60, 150-150.	1.1	35
5	Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology, 2002, 58, 589-592.	1.1	36
6	Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration. Journal of Neuropathology and Experimental Neurology, 2002, 61, 935-946.	1.7	592
7	N-terminally truncated amyloid Î² peptides and Alzheimerâ€™s disease. Neurobiology of Aging, 2001, 22, 345.	3.1	0
8	Molecular consequences of presenilin-1 mutation. Nature, 2001, 411, 655-655.	27.8	4
9	Increased Expression of the Normal Cellular Isoform of Prion Protein in Inclusionâ€Body Myositis, Inflammatory Myopathies and Denervation Atrophy. Brain Pathology, 2001, 11, 182-189.	4.1	37
10	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	3.6	1,179
11	Endogenous APP derivatives oppositely modulate apoptosis through an autocrine loop. NeuroReport, 2000, 11, 1375-1379.	1.2	20
12	Presenilin-1 mutations in Alzheimer's disease. Nature, 2000, 405, 531-532.	27.8	155
13	Lipoperoxidation Is Selectively Involved in Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 393-397.	1.7	82
14	Oxidative Stress Induces Increase in Intracellular Amyloid Î²-Protein Production and Selective Activation of Î²I and Î²II PKCs in NT2 Cells. Biochemical and Biophysical Research Communications, 2000, 268, 642-646.	2.1	169
15	Alternative, Non-secretase Processing of Alzheimer's Î²-Amyloid Precursor Protein during Apoptosis by Caspase-6 and -8. Journal of Biological Chemistry, 1999, 274, 21011-21016.	3.4	148
16	Tau gene mutation in familial progressive subcortical gliosis. Nature Medicine, 1999, 5, 454-457.	30.7	189
17	Tyrosine kinase A-nerve growth factor receptor is antigenically present in dystrophic neurites from a variety of conditions but not in Alzheimer's disease. Neuroscience Letters, 1999, 273, 67-71.	2.1	7
18	Early Glycoxidation Damage in Brains from Down's Syndrome. Biochemical and Biophysical Research Communications, 1998, 243, 849-851.	2.1	120

#	Article	IF	Citations
19	Opposite roles of apolipoprotein E in normal brains and in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15598-15602.	7.1	90
20	Increased amyloidogenic secretion in cerebellar granule cellsâ€‰undergoingâ€‰apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 1247-1252.	7.1	78
21	Amyloidâ€Î² Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. Journal of Neurochemistry, 1998, 70, 2212-2215.	3.9	499
22	Is amyloid Î²-protein glycated in AlzheimerÊ¼s disease?. NeuroReport, 1997, 8, 907-909.	1.2	21
23	Heterogeneity of waterâ€soluble amyloid Î²â€peptide in Alzheimer's disease and Down's syndrome brains. FEBS Letters, 1997, 409, 411-416.	2.8	110
24	Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders. Journal of Neuropathology and Experimental Neurology, 1996, 55, 97-105.	1.7	417
25	Presence of soluble amyloid Î²â€“peptide precedes amyloid plaque formation in Down's syndrome. Nature Medicine, 1996, 2, 93-95.	30.7	342
26	Familial progressive subcortical gliosis. Neurology, 1995, 45, 1062-1067.	1.1	91
27	Apolipoprotein E element 4 allele frequency is not increased in progressive supranuclear palsy. Neurology, 1995, 45, 1764-1765.	1.1	36
28	A novel mechanism of phenotypic heterogeneity demonstrated by the effect of a polymorphism on a pathogenic mutation in the PRNP (prion protein gene). Molecular Neurobiology, 1994, 8, 99-103.	4.0	9
29	Soluble Amyloid Î²-Protein Is a Marker of Alzheimer Amyloid in Brain But Not in Cerebrospinal Fluid. Biochemical and Biophysical Research Communications, 1994, 200, 1598-1603.	2.1	136
30	Preliminary NINDS neuropathologic criteria for Steeleâ€Richardsonâ€Olszewski syndrome (progressive) Tj ETQq0 0 0 rgBT /Overlock 10	1.1	808
31	Research advances in the biology of Alzheimer's disease. Clinics in Geriatric Medicine, 1994, 10, 249-55.	2.6	3
32	Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: a pathological correlate of dementia?. Neuroscience Letters, 1993, 156, 96-98.	2.1	33
33	Fatal familial insomnia and the widening spectrum of prion diseases. British Medical Bulletin, 1993, 49, 980-994.	6.9	34
34	Fatal Familial Insomnia and Familial Creutzfeldt-Jakob Disease: Disease Phenotype Determined by a DNA Polymorphism. Science, 1992, 258, 806-808.	12.6	658
35	Ubiquitin-reactive axons have a widespread distribution and are unrelated to prion protein plaques in Creutzfeldt-Jakob disease. Journal of the Neurological Sciences, 1992, 110, 32-36.	0.6	12
36	GFAP expression of human Schwann cells in tissue culture. Brain Research, 1992, 570, 209-217.	2.2	31

#	Article	IF	Citations
37	Senile plaques in cerebral amyloid angiopathy show accumulation of amyloid precursor protein without cytoskeletal abnormalities. Brain Research, 1992, 593, 299-303.	2.2	13
38	Analysis of the prion protein gene in thalamic dementia. Neurology, 1992, 42, 1859-1859.	1.1	93
39	Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. American Journal of Pathology, 1992, 140, 283-90.	3.8	54
40	Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases. Brain Research, 1991, 558, 43-52.	2.2	15
41	Dystrophic neurites infiltrate extracellular neurofibrillary tangles in Alzheimer disease. Brain Research, 1991, 560, 303-305.	2.2	13
42	Schwann cell GFAP expression increases in axonal neuropathies. Journal of the Neurological Sciences, 1991, 102, 177-183.	0.6	24
43	Amyloid beta protein deposition in brains from elderly subjects with leukoaraiosis. Journal of the Neurological Sciences, 1991, 106, 123-127.	0.6	23
44	Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. Journal of Neuroscience, 1991, 11, 1748-1755.	3.6	147
45	Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2098-2102.	7.1	92
46	Abnormal tauâ€reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer's disease. Neurology, 1991, 41, 391-391.	1.1	48
47	Formic acid treatment exposes hidden neurofilament and tau epitopes in abnormal cytoskeletal filaments from patients with progressive supranuclear palsy and Alzheimer's disease. Neuroscience Letters, 1990, 115, 351-355.	2.1	30
48	The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Annals of Neurology, 1989, 26, 771-778.	5.3	89
49	Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neuroscience Letters, 1989, 103, 259-262.	2.1	9
50	Selective presence of ubiquitin in intracellular inclusions. American Journal of Pathology, 1989, 134, 505-13.	3.8	85
51	Influence of neuronal location on antigenic properties of neurofibrillary tangles. Annals of Neurology, 1988, 23, 604-610.	5.3	45
52	Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Annals of Neurology, 1988, 24, 407-413.	5.3	76
53	Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4501-4505.	7.1	196
54	HLAâ€DR Schwann cell reactivity in peripheral neuropathies of different origins. Neurology, 1988, 38, 848-848.	1.1	76

#	Article	IF	Citations
55	A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. Acta Neuropathologica, 1985, 68, 218-223.	7.7	67